Summary
Using a sensitive and specific method involving high-performance liquid chromatography, urinary levels of four modified nucleosides — pseudouridine (Ψ), 1-methylinosine (m1I), 1-methyladenosine (m1A), and 1-methylguanosine (m1G)-were investigated before and after treatment in 31 patients with cancer of the urinary organs or the female genital tract. Before treatment m1I was the most frequently elevated nucleoside (77%). Pretreatment urinary levels of Ψ, m1I, and m1A in patients with stage 2–4 cancer of the female genital tract were significantly elevated compared to human healthy volunteers (p<0.005). Compared with the other nucleosides, Ψ appeared to correlate more closely with the clinical outcome (progression or regression) of patients with cancer of the female genital tract. In the case of patients with cancer of the urinary organs, m1I followed the clinical outcome better than the other nucleosides measured. Therefore Ψ and m1I seem to be useful for monitoring genito-urinary cancers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borek E, Kerr SJ (1972) Atypical transfer RNA's and their origin in neoplastic cells. Adv Cancer Res 15:163
Borek E, Baliga BS, Gehrke CW, Kuo CW, Belman S, Troll W, Phillip T (1977) High turnover rate of transfer RNA in tumor tissue. Cancer Res 37:3362
Borek E, Sharma OK, Waalkes TP (1983) New applications of urinary nucleoside markers. Recent Results Cancer Res 84:301
Borek E (1984) Toward a universal tumour marker. Tumour Biol 5:1
Davis GE, Suits RD, Kuo KC, Gehrke CW, Waalkes P, Borek E (1977) High-performance liquid chromatographic separation and quatitation of nucleosides in urine and some other biological fluids. Clin Chem 23:1427
Dlugajczyk A, Eiler JJ (1966) Lack of catabolism of s-ribosyluracil in man. Nature 212:611
Heldman DA, Grever MR, Treqyn RW (1983) Differential excretion of modified nucleosides in adult acute leukemia. Blood 61:291
Mach J-P, Jaeger Ph, Bertholet M-M, Ruegsegger C-H, Lossli RM, Pettavel J (1974) Detection of recurrence of large-bowel carcinoma by radioimmunoassay of circulating carcinoembryonic antigen (CEA). Lancet II:535
Mandel LR, Srinivasan PR, Borek E (1966) Origin of urinary methylated purines. Nature 209:586
Mrochek JE, Dinsmore SR, Waalkes TP (1974) Analytic techniques in the separation and identification of specific purine and pyrimidine degradation products of tRNA: Application to urine samples from cancer patients. J Natl Cancer Inst 53:1553
Rasmuson T, Björk GR (1983) Pseudourdine: A modified nucleoside as biological marker in malignant lymphomas. Cancer Detect Prev 6:293
Sjögren HO, Wahren B (1982) Gastrointestinal cancer markers. In: Sell S, Wahren B (eds) Human cancer markers. Human Press, Clifton, New Jersey, pp 105–132
Speer J, Gehrke CW, Kuo KC, Waalkes TP, Borek E (1979) tRNA breakdown products as markers for cancers. Cancer 44: 2120
Srinivasan PR, Borek E (1963) The species variation of RNA methylase. Biochemistry 49:529
Waalkes TP, Dinsmore SR, Mrochek JE (1973) Urinary excretion by cancer patients of the nucleosides N2, N2-dimethylguanosine, 1-methylinosine, and pseudouridine. J Natl Cancer Inst 51:271
Weissman S, Eisen AZ, Lewis M, Karon M, Clark P (1962) Pseudouridine metabolism. III. Studies with isotopically labeled pseudouridine. J Lab Clin Med 60:40
Zimmerman R (1979) Improved performance of a double antibody radioimmunoassay for carcinoembryonic antigen. J Immunol Methods 25:311
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koshida, K., Harmenberg, J., Stendahl, U. et al. Urinary modified nucleosides as tumor markers in cancer of the urinary organs or female genital tract. Urol. Res. 13, 213–218 (1985). https://doi.org/10.1007/BF00261578
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00261578